Paclitaxel/5-FU Promising in Metastatic Breast Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

ROME, Italy-The combination of paclitaxel (Taxol), fluorouracil (5-FU), and leucovorin, with G-CSF support, in pretreated patients with advanced breast cancer had a good toxicity profile and an encouraging response rate in a study from the Regina Elena Cancer Institute, Rome.

ROME, Italy—The combination of paclitaxel (Taxol), fluorouracil (5-FU),and leucovorin, with G-CSF support, in pretreated patients with advancedbreast cancer had a good toxicity profile and an encouraging response ratein a study from the Regina Elena Cancer Institute, Rome.

In the poster presentation, Dr. E. Terzoli described 16 heavily pretreatedadvanced breast cancer patients who received paclitaxel, 135 to 175 mg/m²onday 1 and fluorouracil, 350 to 375 mg/m², plus leucovorin, 10 to 100mg/m², on days 1 to 3. The cycle was repeated every three weeks withG-CSF added to prevent neutropenia.

The combination therapy was delivered as first-line metastatic treatmentin three patients, second-line in five patients, and third-line or higherin eight patients. All patients had received previous anthracyclines, andeight had taken hormones.

Five of 10 evaluable patients had a partial response, and in four ofthese patients, the treatment represented third-line chemotherapy. Overall,the combination was well tolerated.

Related Videos
Exercise and healthy lifestyles can lower the risk of cancer or the symptoms of cancer treatment despite having genetic dispositions, said Neil M. Iyengar, MD.
The Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital includes a social worker, nurse practitioners, a medical oncologist, a radiation oncologist, and surgeons, says Claudia Tellez, MD.
The goal of creating the Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital is to establish a safe space for Hispanic patients, says Claudia Tellez, MD.
Several factors may contribute to the low Hispanic breast cancer population at Northwestern Memorial Hospital, including a lack of resources and a focus on other disease types.
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Hypofractionated radiotherapy yields less financial toxicity than conventionally fractionated radiotherapy in patients with breast cancer who have undergone reconstruction following mastectomy.
Related Content